Could a Low-Dose epilepsy drug protect aging brains?
NCT ID NCT06919926
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether a low-dose extended-release version of levetiracetam (AGB101) can reduce overactivity in the hippocampus, a brain region often overactive in early dementia. Sixty adults aged 50–80 with normal thinking skills will take the drug or a placebo for two weeks each, and brain scans will measure changes. The goal is to see if calming this overactivity could help prevent or delay memory decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University School of Medicine
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGB101 (low-dose levetiracetam, 220 mg extended release tablet)
What this could lead to
If it works, this could point toward a treatment that reduces abnormal brain activity linked to memory loss and dementia in older adults.
What could go wrong
This is a small, early Phase 2 trial with only 60 participants and a short 2-week treatment period. It measures brain imaging changes, not actual memory or thinking improvements, so success is uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.